# Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

> **NCT06685289** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 70 (estimated)

## Conditions studied

- Biliary Malignant Tumors

## Interventions

- **DRUG:** Donafenib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT06685289
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2026-11-15
- **Final completion:** 2027-11-15
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685289, "Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06685289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*